Condition (MeSH)
Donohue Syndrome
ClinicalTrials.gov lists 1 trial for Donohue Syndrome or a narrower condition beneath it. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section
2 sections measured, none recorded · 1 not measured yet · 1 not computed
1 of the 1 trial is tagged with Donohue Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Donohue Syndrome trials start? (1)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2001 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 1 trial evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Donohue Syndrome trials in? (1)
Shown in this order: phase order.
| Phase | Trials |
|---|---|
| Phase 2 | 1 |
How many Donohue Syndrome trials are recruiting? (1)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Donohue Syndrome trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1 |
Which publications cover Donohue Syndrome? (2)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Long-Term Effects of Metreleptin in Rabson-Mendenhall Syndrome on Glycemia, Growth, and Kidney Function. | The Journal of clinical endocrinology and metabolism | 2022 | Yes |
| Metreleptin improves blood glucose in patients with insulin receptor mutations. | The Journal of clinical endocrinology and metabolism | 2013 | Yes |
Prevalence (9)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Donohue syndrome | Point prevalence | <1 / 1 000 000 | Worldwide | Not stated | Unspecified |
| Donohue syndrome | Prevalence at birth | <1 / 1 000 000 | Europe | Not stated | Exact |
| Donohue syndrome | Point prevalence | <1 / 1 000 000 | Europe | Not stated | Exact |
| Donohue syndrome | Prevalence at birth | <1 / 1 000 000 | Europe | Not stated | Unspecified |
| Donohue syndrome | Point prevalence | <1 / 1 000 000 | Worldwide | Not stated | Exact |
Showing 5 of 9 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Donohue syndrome | 508 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Donohue syndrome | 508 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.